Analysis of the actual clinical effect of rasagiline (Azilai) in the treatment of Parkinson's disease

Rasagiline (Rasagiline) is a selective monoamine oxidase-B (MAO-B) inhibitor, mainly used for the monotherapy or combination treatment with levodopa in Parkinson's disease (PD). By inhibiting MAO-B, rasagiline can reduce the breakdown of dopamine in the central nervous system, thereby increasing the amount of dopamine available, improving motor symptoms, and delaying disease progression. This mechanism makes it an important treatment option for patients with early-stage PD and those with “on--off” fluctuations.

In clinical studies, rasagiline monotherapy can significantly improve motor symptom scores (such asUPDRS scores) and relieve tremor, stiffness and bradykinesia in patients with early-stage Parkinson's disease. Rasagiline prolonged progression-free time and improved quality of life compared with placebo. For mid-to-late-stage patients who require combined levodopa treatment, rasagiline can reduce levodopa dose requirements, delay the occurrence of "crossover effect" and "on-off" fluctuations, thereby improving overall motor control and drug compliance.

Real-world studies show that rasagiline is well tolerated in long-term use. Common adverse reactions include headache, insomnia, gastrointestinal discomfort and mild blood pressure changes, but most patients can tolerate it and do not need to discontinue the drug. Compared with other MAO-B inhibitors, rasagiline is more selective and has fewer drug interactions, making it safer in combination treatment regimens. At the same time, long-term observation shows that it has little impact on cognitive function and mental state, and is suitable for long-term use by elderly patients.

Overall, rasagiline has significant efficacy advantages in the clinical application of Parkinson's disease. It can be used as a monotherapy in the early stage to improve basic motor symptoms, and can also be used as an auxiliary drug to optimize the treatment plan in the middle and late stages. Through reasonable dose management and individualized treatment, rasagiline can improve patients' quality of life, delay disease progression, and play an important role in reducing levodopa-related complications, providing a reliable and safe treatment option for patients with Parkinson's disease.

Reference link:https://www.drugs.com